Reading Time: 2 minutes
For me, MiniMed Group (MMED) is currently one of the most exciting special situations in the MedTech sector. The company develops insulin pumps, glucose sensors, and smart insulin pens for people with diabetes. Sensors continuously measure blood sugar levels, while algorithms automatically control insulin delivery. Since the IPO in March, the separation from Medtronic has overshadowed operational development. At around 20% below its all-time high, I see an attractive entry opportunity. After the planned end of the stock exchange on October 9, the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
